phosphosulfate synthetase 2 (Papss2) activity: a putative model of human PAPSS2 deficiency-associated arthrosis. Osteoarthritis Cartilage 13: 418–425. 12. Wang WZ, Guo X, Duan C, Ma WJ, Zhang YG, et al. (2009) Comparative analysis of gene expression profiles between the normal human cartilage and the one with endemic osteoarthritis. Osteoarthritis and Cartilage 17: 83–90. 13. Ma WJ, Guo X, Liu JT, Liu RY, Hu JW, et al. (2011) Proteomic changes in articular cartilage of human endemic osteoarthritis in China. Proteomics 11: 2881–2890. 14. Wang W, Guo X, Chen J, Xu P, Lammi MJ (2008) Morphology and phenotype expression of types I, II, III, and X collagen and MMP-13 of chondrocytes cultured from articular cartilage of Kashin-Beck Disease. J Rheumatol 35: 696– 702. 15. Wang S, Guo X, Wu XM, Lammi MJ (2012) Genome-wide gene expression analysis suggests an important role of suppressed immunity in pathogenesis of Kashin-Beck disease. PLoS One 7: e28439. 16. Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, et al. (2009) Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med 360: 2310–2318. 17. Xu ZH, Freimuth RR, Eckloff B, Wieben E, Weinshilboum RM (2002) Human 39-phosphoadenosine 59-phosphosulfate synthetase 2 (PAPSS2) pharmacoge- netics: gene resequencing, genetic polymorphisms and functional characteriza- tion of variant allozymes. Pharmacogenetics 12: 11–21. 18. Stelzer C, Brimmer A, Hermanns P, Zabel B, Dietz UH (2007) Expression profile of Papss2 (39-phosphoadenosine 59-phosphosulfate synthase 2) during cartilage formation and skeletal development in the mouse embryo. De- velopmental Dynamics 236: 1313–1318. 19. Beckmann MP, Betsholtz C, Heldin CH, Westermark B, Dimarco E, et al. (2000) Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. Science 77: 34–38. 20. Ozcaka O, Nalbantsoy A, Bicakci N, Kose T, Buduneli N (2011) Plasma Levels of C-Telopeptide Pyridinoline Cross-Links of Type I Collagen and Osteocalcin in Chronic Periodontitis. Inflammation. 21. Genevieve D, Heron D, El Ghouzzi V, Prost-Squarcioni C, Le Merrer M, et al. (2005) Exclusion of the dymeclin and PAPSS2 genes in a novel form of spondyloepimetaphyseal dysplasia and mental retardation. European Journal of Human Genetics 13: 541–546. 22. Rossi A, Bonaventure J, Delezoide AL, Cetta G, Superti-Furga A (1996) Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. J Biol Chem 271: 18456–18464. 23. Weller NJ, Rattan SIS, New York Academy of Sciences (2007) Healthy aging and longevity: third international conference. Boston, Mass.: Published by Blackwell Pub. On behalf of the New York Academy of Sciences. xv, 466 p. 24. Ikeda T, Mabuchi A, Fukuda A, Hiraoka H, Kawakami A, et al. (2001) Identification of sequence polymorphisms in two sulfation-related genes, PAPSS2 and SLC26A2, and an association analysis with knee osteoarthritis. J Hum Genet 46: 538–543. 25. Apte UM, Banerjee A, McRee R, Wellberg E, Ramaiah SK (2005) Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol Appl Pharmacol 207: 25–38. 26. Merry K, Dodds R, Littlewood A, Gowen M (1993) Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci 104 (Pt 4): 1013–1020. 27. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K (2002) Activations of ERK1/2 and JNK by transforming growth factor beta negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem 277: 36024–36031. 28. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K (2002) Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 17: 1190–1199. 29. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS (2001) The loss of Smad3 results in a lower rate of bone formation and osteopenia through Function of PAPSS2 in Osteoblasts dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 16: 1754–1764. 30. Kaji H, Naito J, Inoue Y, Sowa H, Sugimoto T, et al. (2008) Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway. Horm Metab Res 40: 746–751. 31. Kaji H, Naito J, Sowa H, Sugimoto T, Chihara K (2006) Smad3 differently affects osteoblast differentiation depending upon its differentiation stage. Horm Metab Res 38: 740–745. 32. Sowa H, Kaji H, Iu MF, Tsukamoto T, Sugimoto T, et al. (2003) Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J Biol Chem 278: 52240– 52252. 33. Wang Y, Zheng Q, Guo X, Wu Y, Hao J (2005) Influence of exogenous TGFbeta1 on the expression of smad2 and smad3 in rat bone marrow-derived mesenchymal stem cells. J Huazhong Univ Sci Technolog Med Sci 25: 68–71. 34. Zheng Q, Wang Y, Gu X (2005) Wild-type Smad3 gene enhances the osteoblastic differentiation of rat bone marrow-derived mesenchymal stem cells in vitro. J Huazhong Univ Sci Technolog Med Sci 25: 674–678. 35. Wan M, Shi X, Feng X, Cao X (2001) Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. J Biol Chem 276: 10119–10125. 36. Fukunishi N, Katoh I, Tomimori Y, Tsukinoki K, Hata R, et al. (2010) Induction of DeltaNp63 by the newly identified keratinocyte-specific transform- ing growth factor beta Signaling Pathway with Smad2 and IkappaB Kinase alpha in squamous cell carcinoma. Neoplasia 12: 969–979. 37. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, et al. (2010) Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer 10: 652. 38. Pessah M, Prunier C, Marais J, Ferrand N, Mazars A, et al. (2001) c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc Natl Acad Sci U S A 98: 6198–6203. 39. Wrana JL (1998) TGF-beta receptors and signalling mechanisms. Miner Electrolyte Metab 24: 120–130. 40. Zheng Z, Zhang L, Kong L, Wang A, Gong Y, et al. (2009) The behavior of MC3T3-E1 cells on chitosan/poly-L-lysine composite films: effect of nanotopo- graphy, surface chemistry, and wettability. J Biomed Mater Res A 89: 453–465. 41. Ozeki K, Aoki H, Fukui Y (2008) The effect of adsorbed vitamin D and K to hydroxyapatite on ALP activity of MC3T3-E1 cell. J Mater Sci Mater Med 19: 1753–1757. 42. Schneider GB, Whitson SW, Cooper LF (1999) Restricted and coordinated expression of beta3-integrin and bone sialoprotein during cultured osteoblast differentiation. Bone 24: 321–327. 43. Ovchinnikov D (2009) Alcian blue/alizarin red staining of cartilage and bone in mouse. Cold Spring Harb Protoc 2009: 5170. 44. Yamakawa K, Iwasaki H, Masuda I, Ohjimi Y, Honda I, et al. (2003) The utility of alizarin red s staining in calcium pyrophosphate dihydrate crystal deposition disease. J Rheumatol 30: 1032–1035. 45. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, et al. (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60: 6001–6007. 46. Rungby J, Kassem M, Eriksen EF, Danscher G (1993) The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background. Histochem J 25: 446–451. 47. Yang S, Li YP (2007) RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation. Genes Dev 21: 1803– 1816. 48. Steenhard BM, Isom K, Stroganova L, St John PL, Zelenchuk A, et al. (2010) Deletion of von Hippel-Lindau in glomerular podocytes results in glomerular basement membrane thickening, ectopic subepithelial deposition of collagen a1a2a1(IV), expression of neuroglobin, and proteinuria. Am J Pathol 177: 84– 96. PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e43475